Short QT syndrome type 1 (SQT1) results from gain-of-function mutations in the Kv11.1 (hERG) channel encoded by the KCNH2 gene, and is the best studied SQT subtype with respect to pharmacological treatment. This evidence concerns the gene KCNH2 and Familial short QT syndrome.